ATE333280T1 - Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen - Google Patents
Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungenInfo
- Publication number
- ATE333280T1 ATE333280T1 AT03703621T AT03703621T ATE333280T1 AT E333280 T1 ATE333280 T1 AT E333280T1 AT 03703621 T AT03703621 T AT 03703621T AT 03703621 T AT03703621 T AT 03703621T AT E333280 T1 ATE333280 T1 AT E333280T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- medication
- mutation
- production
- low molecular
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000004568 DNA-binding Effects 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 abstract 1
- 230000007420 reactivation Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35783102P | 2002-02-21 | 2002-02-21 | |
| SE0200523A SE0200523D0 (sv) | 2002-02-21 | 2002-02-21 | New compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE333280T1 true ATE333280T1 (de) | 2006-08-15 |
Family
ID=27759836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03703621T ATE333280T1 (de) | 2002-02-21 | 2003-02-07 | Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7659278B2 (de) |
| EP (1) | EP1476166B1 (de) |
| AT (1) | ATE333280T1 (de) |
| AU (1) | AU2003206329B2 (de) |
| CA (1) | CA2476825C (de) |
| DE (1) | DE60306896T2 (de) |
| ES (1) | ES2269975T3 (de) |
| WO (1) | WO2003070250A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004224488B2 (en) * | 2003-03-24 | 2009-09-10 | Aprea Therapeutics Ab | Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53 |
| SE0400708D0 (sv) * | 2004-03-22 | 2004-03-22 | Aprea Ab | New compounds and use thereof |
| US7790474B1 (en) | 2005-07-15 | 2010-09-07 | Schering Corporation | p53 modulators |
| ITNA20090047A1 (it) * | 2009-07-16 | 2011-01-17 | Adele Bolognese | Agenti antitumorali con attività inibitoria di proteine di prenilazione, processo di preparazione e impieghi in campo medico |
| PL2525796T3 (pl) * | 2010-01-21 | 2016-09-30 | Wodny roztwór zawierający 3 chinuklidynony do leczenia choroby hiperproliferacyjnej, autoimmunologicznej i serca | |
| CN104860994A (zh) * | 2014-02-20 | 2015-08-26 | 中国药科大学 | 3-奎宁环酮类含磷化合物的制备及其医药用途 |
| WO2019173806A1 (en) * | 2018-03-09 | 2019-09-12 | Texas Tech University System | Compositions and methods for the diagnosis and treatment of alt cancer |
| EP3806850A2 (de) * | 2018-06-15 | 2021-04-21 | Ideaya Biosciences, Inc. | Verfahren zur hemmung proliferativer zellen |
| KR20210062044A (ko) | 2018-09-20 | 2021-05-28 | 아프레아 테라퓨틱스 에이비 | 퀴누클리딘-3-온 유도체와 암 치료에서 이의 용도 |
| EP4031136A1 (de) | 2019-09-18 | 2022-07-27 | Aprea Therapeutics AB | Kombinationstherapie mit einem p53-reaktivator und einem inhibitor eines antiapoptotischen proteins der bcl-2-familie |
| WO2021170772A1 (en) | 2020-02-26 | 2021-09-02 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling |
| WO2021180338A1 (en) | 2020-03-09 | 2021-09-16 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant |
| WO2022175402A1 (en) | 2021-02-18 | 2022-08-25 | Aprea Therapeutics Ab | Quinuclidine-3-one derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| AU2001284645A1 (en) * | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| CA2423192C (en) * | 2000-09-20 | 2010-11-23 | Karolinska Innovations Ab | 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors |
| DE60209471D1 (de) * | 2001-03-29 | 2006-04-27 | Topo Target As Copenhagen Koeb | Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii |
-
2003
- 2003-02-07 DE DE60306896T patent/DE60306896T2/de not_active Expired - Lifetime
- 2003-02-07 CA CA2476825A patent/CA2476825C/en not_active Expired - Lifetime
- 2003-02-07 US US10/505,407 patent/US7659278B2/en not_active Expired - Lifetime
- 2003-02-07 ES ES03703621T patent/ES2269975T3/es not_active Expired - Lifetime
- 2003-02-07 AT AT03703621T patent/ATE333280T1/de active
- 2003-02-07 WO PCT/SE2003/000206 patent/WO2003070250A1/en not_active Ceased
- 2003-02-07 EP EP03703621A patent/EP1476166B1/de not_active Expired - Lifetime
- 2003-02-07 AU AU2003206329A patent/AU2003206329B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003206329B2 (en) | 2007-08-09 |
| AU2003206329A1 (en) | 2003-09-09 |
| DE60306896D1 (de) | 2006-08-31 |
| EP1476166B1 (de) | 2006-07-19 |
| CA2476825C (en) | 2011-04-05 |
| EP1476166A1 (de) | 2004-11-17 |
| US20050090510A1 (en) | 2005-04-28 |
| US7659278B2 (en) | 2010-02-09 |
| DE60306896T2 (de) | 2007-02-15 |
| WO2003070250A1 (en) | 2003-08-28 |
| ES2269975T3 (es) | 2007-04-01 |
| CA2476825A1 (en) | 2003-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60136473D1 (de) | Verwendung von 1-azabicyclo(2.2.2)octan-3-on-derivaten zur behandlung von krebstumoren | |
| ATE333280T1 (de) | Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen | |
| CY1113039T1 (el) | Ηλεκτρικο και μηλονικο αλας τρανς-4-(1r,3s)-6-χλωρο-3-φαινυλινδαν-1-υλο)-1,2,2-τριμεθυλοπιπεραζινης και η χρηση ως φαρμακο | |
| DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| DE60010234D1 (de) | 2-amino-6-anilino-purine und deren verwendung als arzneimittel | |
| ATE348808T1 (de) | Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten | |
| DE60014670D1 (de) | Antipicornavirale verbindungen und zusammensetzungen, ihre pharmazeutische verwendung, und materialien für ihre synthese | |
| DE10337184A1 (de) | Substituierte 3-Pyrrolidin-Indol-Derivate | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| DE60136826D1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| DE60233433D1 (de) | PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN | |
| ATE339205T1 (de) | (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen | |
| ATE457027T1 (de) | Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht | |
| ATE383853T1 (de) | Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
| DE602004015406D1 (de) | Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen | |
| DE60326069D1 (de) | 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen | |
| ATE392471T1 (de) | Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren | |
| DE602006016799D1 (de) | NEUE, HYALURONSÄURE ODER HYALURONSàURE DERIVATE UND COLLAGENASE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR TOPISCHEN BEHANDLUNG VON WUNDEN, VERBRENNUNGEN UND GESCHWÜREN | |
| ATE383870T1 (de) | Behandlung von neurodegenerative krankheiten mit gpr49 | |
| ATE309817T1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
| DE602004031631D1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
| DE602004021363D1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
| EP1663201A4 (de) | Verwendung von neuen 2-oxo-heterozyklischen verbindungen sowie diesen enthaltenden pharmazeutischen zubereitungen | |
| ATE530525T1 (de) | Piperidine und verwandte verbindungen zur behandlung von demenz | |
| ATE537832T1 (de) | Mittel zur prävention und behandlung von lebererkrankungen mit einem pyrazolopyrimidin- derivat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1476166 Country of ref document: EP |